 ganciclovir or foscarnet as preemptive therapy for cytomegalovirus after allogeneic hematopoietic cell transplantation is associated with myelosuppression and nephrotoxicity respectively . We analyzed a cohort of CMV seropositive R

@highlight We assessed toxicities by day 100 associated with preemptive therapy PET in a cohort of cytomegalovirus seropositive hematopoietic cell transplantation recipients.
@highlight Neutropenia occurred in 41.8 of PET versus 28.6 of no PET patients 
@highlight  .0009 .
@highlight Acute kidney injury AKI occurred in 10.2 of PET versus 7.8 of no PET patients 
@highlight  .19 .
@highlight In multivariate models PET increased the risk of neutropenia and AKI by 1.8 and 2.8 fold respectively.
